For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
|Articles|May 23, 2001
Director named for imaging institute
Donna J. Dean is the acting director of the new National Institute of Biomedical Imaging and Bioengineering. The institute, approved by Congress earlier this year, will focus on fundamental research into medical imaging. Dean has served as a senior
Advertisement
Donna J. Dean is the acting director of the new National Institute of Biomedical Imaging and Bioengineering. The institute, approved by Congress earlier this year, will focus on fundamental research into medical imaging. Dean has served as a senior scientific adviser to the director of NIH for the last three years.
Advertisement
Related to this article
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a study involving over 2,800 people who had brain MRI scans, researchers found that people in the most disadvantaged neighborhoods had 37 percent higher white matter hyperintensity volume (WMHV) on average in comparison to people in the least disadvantaged areas.
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
Amid the explosion of imaging volume, an emerging silver lining is increasing recognition from referring clinicians of the time and value radiologists provide to facilitate patient care.
In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.
Catch up on the top radiology content of the past week.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Prostate MRI Study Links Lower ACD Values on DWI to Higher Long-Term Risk of Distant Metastases
2
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
3
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
4
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
5